CSF Multianalyte Profile Distinguishes Alzheimer and Parkinson Diseases

Zhang, Jing; Sokal, Izabela; Peskind, Elaine R.; Quinn, Joseph F.; Jankovic, Joseph; Kenney, C.; Chung, Kathryn A.; Millard, Steven P.; Nutt, John G.; Montine, Thomas J.

doi:10.1309/w01y0b808emeh12l

Cited by 250 publications

(212 citation statements)

References 17 publications

Supporting

Mentioning

194

Contrasting

Unclassified

Order By: Relevance

“…As many Ab-binding proteins, such as TTR, apoE, apoJ, and apoA1, are known to accumulate with Ab in amyloid No Ab bands were detected in the littermate mice; n ¼ 4 each cases deposits 5,17 and the level of DBP in CSF is increased in AD patients, 11,15,16 we examined whether DBP is present in the amyloid plaques of brains from AD patients and transgenic animal model of AD. We double-stained human AD and control brain with antibodies against Ab (4G8) and DBP.…”

Section: Resultsmentioning

confidence: 99%

“…Although the level of DBP in CSF has been known to be increased in AD patients, and several lines of evidence have suggested that DBP plays a role in AD, 11,15,16,32 there is no direct evidence of whether or how DBP affects AD-related pathology. Our data clearly show that DBP interacts directly with Ab and reduces the formation of aggregated Ab.…”

Section: Discussionmentioning

confidence: 99%

“…32,38,39 Many studies have also shown alterations in the concentration of DBP in the CSF of AD patients, who demonstrated upregulation of DBP expression. 11,15,16 Based on these reports, Ab-binding proteins, including DBP, might provide effective diagnostic tools or biomarkers for AD. 32,38,39 It has been suggested that upregulation of neuroprotective and Ab-sequestering proteins, such as ADNP and cystatin C, in response to AD represents an intrinsic compensatory response that may counteract the progression of the disease.…”

Section: Discussionmentioning

confidence: 99%

“…Several other studies also have shown that the level of DBP in CSF is increased in AD patients and suggested that this plays a role in the pathology of AD. 15,16 However, the functions of extracellular DBP in AD have not yet been elucidated.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Vitamin D-binding protein interacts with Aβ and suppresses Aβ-mediated pathology

et al. 2012

View full text Add to dashboard Cite

The level of vitamin D-binding protein (DBP) is increased in the cerebrospinal fluid of patients with Alzheimer's disease (AD), suggesting a relationship with its pathogenesis. In this study, we investigated whether and how DBP is related to AD using several different approaches. A pull-down assay and a surface plasmon resonance binding assay indicated direct interactions between purified DBP and amyloid beta (Ab), which was confirmed in the brain of AD patients and transgenic AD model mice by immunoprecipitation assay and immunohistochemical double-staining method. Moreover, atomic force microscopic examination revealed that DBP reduced Ab aggregation in vitro. DBP also prevented Ab-mediated death in cultured mouse hippocampal HT22 cell line. Finally, DBP decreased Ab-induced synaptic loss in the hippocampus and rescued memory deficits in mice after injection of Ab into the lateral ventricle. These results provide converging evidence that DBP attenuates the harmful effects of Ab by a direct interaction, and suggest that DBP is a promising therapeutic agent for the treatment of AD.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Vitamin D-binding protein interacts with Aβ and suppresses Aβ-mediated pathology

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Using CSF of PD patients, Zhang et al 80 reported on the first large scale proteomic experiment, the presence of novel BMs for PD and AD. Of these BMs, however, only A␤ and tau proteins displayed different levels among controls, AD and PD, and between AD and PD as expected.…”

Section: Fig 2 Pre-diagnostic Phase Of Parkinson's Disease (Pd)mentioning

confidence: 99%

Biomarkers for Evaluation of Clinical Efficacy of Multipotential Neuroprotective Drugs for Alzheimer's and Parkinson's Diseases

et al. 2009

View full text Add to dashboard Cite

Summary: During the last century, the world population has shown a staggering increase in its proportion of elderly members and thus neurodegenerative diseases like Alzheimer's disease (AD) and Parkinson's disease (PD), respectively, are becoming an increasing burden on society. Among the diverse, significant challenges facing clinicians, is the improvement of diagnostic measures to detect early and subtle symptoms, a phase in which prevention efforts might be expected to have their greatest impact and provide a measure of disease progression that can be evaluated during the course of drug treatment. At present, clinical diagnosis of AD and PD is based on a constellation of symptoms and manifestations, although the disease originated several years earlier. Given the multiple etiological nature of AD and PD, it is reasonable to assume that the initial causative pathobiological processes may differ between the affected individuals. Therefore, the availability of biological markers or biomarkers will help not only early disease diagnosis, but also delineate the pathological mechanisms more definitively and reliably than the traditional cognitive and neurological phenotypes. In the current article, we review the literature on biochemical, genetic, and neuroimaging biomarkers and discuss their predictive value as indicative for disease vulnerability to detect individuals at risk for PD and AD, and to determine the clinical efficacy of novel, disease-modifying (neuroprotective) strategies.

show abstract